The Clermont-Ferrand University Hospital has reached a new milestone in the management of patients suffering from aortic stenosis by joining the very first French centers to implant Medtronic’s new Evolut™ FX+ valve, tested during its national preview week.
This advancement marks an important turning point for interventional cardiology and demonstrates our institution’s continued commitment to innovation in the service of patient care.
A new, more advanced generation of TAVI valve
The Evolut™ FX+ valve represents the latest advancement in TAVI (Transcatheter Aortic Valve Implantation) devices, a minimally invasive technique that replaces the aortic valve without open‑heart surgery.
This technology stands out thanks to a completely redesigned structure, featuring in particular:
Improved visibility
The new design includes three windows that are four times larger within the stent, offering better visualization and enhanced control during the procedure. This improvement increases precision for interventional cardiologists.
Easier coronary access
The enlarged stent cells now provide significantly simplified access to the coronary arteries for future interventions. This is a key advantage for patients who may require coronary procedures after valve implantation.
Sustained performance
Despite the larger openings in the structure, the valve maintains the proven radial strength of previous generations, ensuring stability, proper expansion, and long‑term durability of the device.
A collective commitment in the service of innovation
The implantation of this new valve at Clermont‑Ferrand University Hospital was carried out thanks to the joint mobilization of the medical and paramedical teams of the interventional cardiology department.
This success reflects:
- their technical expertise,
- their ability to rapidly integrate innovations,
- and their commitment to offering patients the best available therapeutic solutions.
A direct benefit for patients
For people suffering from severe aortic stenosis, this new generation of valve offers:
- a safer and more precise intervention,
- easier coronary access for future needs,
- improved visibility during the procedure,
- and potentially increased durability of the implanted device.
It represents a genuine breakthrough that enhances both procedural quality for practitioners and long‑term outcomes for patients.
An important milestone for the Clermont‑Ferrand University Hospital
By being among the first French centers to use the Evolut™ FX+ valve, the Clermont‑Ferrand University Hospital confirms its role as a key player in the development of innovative technologies in interventional cardiology.
A big congratulations to all the teams involved for this new achievement in the service of patients.
